奥瑞利珠单抗
| 单克隆抗体 | |
|---|---|
| 种类 | 完整抗体 |
| 目标 | CD20 |
| 临床资料 | |
| 商品名 | Ocrevus |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a617026 |
| 核准状况 | |
| 怀孕分级 | |
| 给药途径 | 静脉注射, 皮下注射 |
| ATC码 | |
| 法律规范状态 | |
| 法律规范 |
|
| 识别信息 | |
| CAS号 | 637334-45-3  |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化学信息 | |
| 化学式 | C6494H9978N1718O2014S46 |
| 摩尔质量 | 145,818.03 g·mol−1 |
奥瑞利珠单抗又译为奥克莱珠单抗（INN：Ocrelizumab）用于治疗多发性硬化症[10][11]。主要是针对复发型（relapsing MS，RMS）和原发性进展型（primary progressive MS，PPMS)[11]。透过静脉缓慢注射[11]。
常见副作用包括皮疹、瘙痒、呼吸困难和感染[11]。其他副作用包括可能癌症[10]。孕期使用的安全性不明[12]。它是一种单克隆抗体，可与B细胞上的CD20结合而减少其活性[11]。
奥瑞利珠单抗于2017年及2018年在美国及欧洲取得医疗使用许可[10] [11]。
参考文献
[编辑]- ^ Ocrelizumab (Ocrevus) Use During Pregnancy. Drugs.com. 13 August 2019 [28 March 2020].
- ^ 2.0 2.1 Ocrevus PI (PDF). [31 March 2024].
- ^ Prescription medicines: registration of new chemical entities in Australia, 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [9 April 2023].
- ^ Prescription medicines and biologicals: TGA annual summary 2017. Therapeutic Goods Administration (TGA). 21 June 2022 [31 March 2024].
- ^ Regulatory Decision Summary for Ocrevus. Drug and Health Product Register. 23 October 2014.
- ^ Neurological therapies. Health Canada. 9 May 2018 [13 April 2024].
- ^ Ocrevus 300 mg concentrate for solution for infusion - Summary of Product Characteristics (SmPC). (emc). 30 December 2019 [28 March 2020].
- ^ Ocrevus- ocrelizumab injection. DailyMed. 13 December 2019 [25 April 2020].
- ^ Ocrevus EPAR. European Medicines Agency (EMA). 11 January 2018 [25 April 2020].
本文含有此来源中属于公有领域的内容。
- ^ 10.0 10.1 10.2 Ocrelizumab Monograph for Professionals. Drugs.com. [6 November 2021]. （原始内容存档于17 March 2021） （英语）.
- ^ 11.0 11.1 11.2 11.3 11.4 11.5 Ocrevus EPAR. European Medicines Agency (EMA). [25 April 2020]. （原始内容存档于27 March 2020）. 本文含有此来源中属于公有领域的内容。
- ^ Ocrelizumab (Ocrevus) Use During Pregnancy. Drugs.com. [6 November 2021]. （原始内容存档于28 March 2020） （英语）.
外部链接
[编辑]- Clinical trial number NCT01247324 for "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis" at ClinicalTrials.gov
- Clinical trial number NCT01412333 for "A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis" at ClinicalTrials.gov
- Clinical trial number NCT01194570 for "A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis" at ClinicalTrials.gov
